Anapharm Bioanalytics offers an array of Ligand Binding Assays (LBA), including cell-based assays, and LC-MS/MS technology platforms tailored to support large molecule development programs from early preclinical through Phase I-III clinical stages:
LBA and LC-MS/MS analytical method development and validation.
Method transfer, optimization and cross-validation of sponsor-supplied methods.
Quantitative analysis in biological fluids and tissues for Pharmacokinetic, Pharmacodynamic (PK/PD) and Toxicokinetic (TK) studies including:
Anti-drug antibodies (ADA): safety assessment following a tiered approach including ADA screening and Positive ADA confirmation.
Neutralizing Antibodies (NAbs) by non-cell based (CLBA) and cell-based assays (CBA).
Cell-based assays for cell proliferation, ligand Stimulated Cell Signalling, Protein Secretion, Reporter Gene, etc. (read more about our Cell Lab below)
Enzyme-linked immunosorbent assay (ELISA) with colorimetric, fluorescence and chemiluminescence readouts. Validation of commercially available ELISA kits.